Evidence map›Paper›PMID 41898572›Full record

ArticleInternational journal of molecular sciences2026

Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study.

Tatsuro Jo, Yoshio Saburi, Taro Masunari, Kazuhiro Noguchi, Takahiro Sakai, Jun Taguchi, Eiichi Ohtsuka, Nobuo Sezaki, Ritsuko Kubota-Koketsu, Toru Kiguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
Yoshio SaburiDepartment of Hematology, Oita Prefectural Hospital, Toyo 2-8-1, Oita City 870-8511, Oita, Japan.
Taro MasunariDepartment of Infectious Disease, Chugoku Central Hospital, Miyukicho Oazakamiiwanari 148-13, Fukuyama City 720-0001, Hiroshima, Japan.ORCID 0000-0002-9952-022X
Kazuhiro NoguchiDepartment of Clinical Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
Takahiro SakaiDepartment of Clinical Laboratory, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
Jun TaguchiDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Mori-machi 3-15, Nagasaki City 852-8511, Nagasaki, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Toyo 2-8-1, Oita City 870-8511, Oita, Japan.
Nobuo SezakiDepartment of Hematology, Chugoku Central Hospital, Miyukicho Oazakamiiwanari 148-13, Fukuyama City 720-0001, Hiroshima, Japan.
Ritsuko Kubota-KoketsuSpecimen Analysis Team, Human Resource Development Division, Center for Infectious Disease Education and Research, The University of Osaka, Yamadaoka 2-2, Suita City 565-0871, Osaka, Japan.ORCID 0000-0002-0623-038X
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Miyukicho Oazakamiiwanari 148-13, Fukuyama City 720-0001, Hiroshima, Japan.

Funding

Bristol Myers Squibb CA180-712
6 · The paper itself

Abstract

We prospectively evaluated whether cytotoxic T-lymphocyte (CTL) activation and T-cell receptor (TCR) Vβ clonality predict treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) cessation in chronic-phase chronic myeloid leukemia (CML). Forty-five patients with sustained deep molecular response (DMR) were enrolled (On-TKI,

Indexed as

Immunologic MemoryLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsReceptors, Antigen, T-Cell, alpha-betaT-Lymphocytes, CytotoxicAdultAgedFemaleHumansLymphocyte ActivationMaleMiddle AgedProspective StudiesRemission InductionTreatment InterruptionProtein Kinase InhibitorsReceptors, Antigen, T-Cell, alpha-betachronic myeloid leukemiacytotoxic T lymphocytedeep molecular responseflow cytometryT-cell receptor repertoiretreatment-free remissiontyrosine kinase inhibitor

Identifiers

PMID41898572
PMCPMC13026259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.